FDA widening probe on generic drug impuritiesAngiotensin II receptor blockers, FDA, FDA/Regulatory, Generics, Hypertension, Impurities, ProbesThe Food and Drugs Administration is expanding the regulatory agency’s investigation into impurities in U.S. generic drugs beyond a class of hypertension drugs known as angiotensin II receptor blockers (ARBs). Read more August 28, 2019/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2019-08-28 10:33:122019-08-28 13:23:07FDA widening probe on generic drug impurities
